The Institute aims to develop a platform of knowledge in translational immunology which will become a reference point for scientific excellence and the transfer of innovative concepts from research to industry. With this objective, research and training programmes are focused on selected areas of medical immunology of high relevance and potential in terms of public health and pharmaceutical development. As a partner of BioWin, the Health Cluster of Wallonia, the Institute develops international collaborations enrolling the Walloon Region in the European Research Area. | |
|
 |
 The Institute is located in the BioPark of Charleroi-Brussels South where the major biomedical research infrastructures of the Université Libre de Bruxelles have been established since 1999. It currently encompasses 800 m2 of laboratory surfaces including a biosafety level III unit, and a 400 m2 Specific Pathogens Free (SPF) animal house facility. Equipment is organized into technology platforms dedicated to flow cytometry and high-speed cell sorting, molecular biology, and micro-surgery. A new center for multimodal molecular imaging located in the same building will allow live imaging based on pet-scan, magnetic resonance and optical microscopy technologies. | |
|
 |
 Currently, the Institute has a headcount of 74 people including 28 senior investigators, 20 PhDs students, 16 technicians and a management team of 10 individuals. The Institute entices researchers from all over the world. In recent years, research fellows were welcomed from China, the USA, India, Mexico, France, the United Kingdom, Turkey, Romania, Bulgaria and the Netherlands. | |
|
| Our Full Brochure 2009-2010 | |
 You can download here our full brochure 2009-2010 | |
|
|
   
|   | Latest news |  |
| | - Recent publication in Hum Immunol> Read more | | |
|
 | Interesting Links |  |
| | BioWin Pôle de Compétitivité Santé de Wallonie IBMM Institut de Biologie et de Médecine Moléculaires GIGA Groupe Interdisciplinaire de Génoprotéomique Appliquée Immunehealth provides Services to Biotech Companies and Biopharma in the field of Immunology | | |
|
|
|